Immunoglobulin G, Plasma Cells, and Lymphocytes in the Murine Vagina after Vaginal or Parenteral Immunization with Attenuated Herpes Simplex Virus Type 2

EARL L. PARR* AND MARGARET B. PARR

Department of Anatomy, School of Medicine, Southern Illinois University, Carbondale, Illinois 62901-6523

Received 17 November 1997/Accepted 18 February 1998

This investigation evaluated immunity to vaginal herpes simplex virus type 2 (HSV-2) infection after local or parenteral immunization with attenuated HSV-2. Vaginal immunization induced sterilizing immunity against challenge with a high dose of wild-type virus, whereas parenteral immunizations protected against neurologic disease but did not entirely prevent infection of the vagina. Vaginal immunization caused 86- and 31-fold increases in the numbers of immunoglobulin G (IgG) plasma cells in the vagina at 6 weeks and 10 months after immunization, whereas parenteral immunizations did not increase plasma cell numbers in the vagina. Vaginal secretion/serum titer ratios and specific antibody activities in vaginal secretions and serum indicated that IgG viral antibody was produced in the vagina and released into vaginal secretions at 6 weeks and 10 months after vaginal immunization but not after parenteral immunizations. In contrast to the case for plasma cells, the numbers of T and B lymphocytes in the vagina were similar in vaginally and parenterally immunized mice. Also, lymphocyte numbers in the vagina were markedly but similarly increased by vaginal challenge with HSV-2 in both vaginally and parenterally immunized mice. Lymphocyte recruitment to the vagina after virus challenge appeared to involve memory lymphocytes, because it was not observed in nonimmunized mice. Thus, local vaginal immunization with attenuated HSV-2 increased the number of IgG plasma cells in the vagina and increased vaginal secretion/serum titer ratios to 3.0- to 4.7-fold higher than in parenterally immunized groups but caused little if any selective homing of T and B lymphocytes to the vagina.

An understanding of the immune mechanisms that protect the female genital tract against infections in animal models is essential for development of vaccines to protect women against sexually transmitted diseases (35). A mouse model of immunity against vaginal herpes simplex virus type 2 (HSV-2) infection has been described by McDermott and coworkers (22) and modified by Parr et al. (32). In this model, vaginal immunization with attenuated HSV-2 elicits immunity against a subsequent vaginal challenge with wild-type virus. The protective immunity in this model is quite strong (34). Twenty-four hours after immune mice were challenged in the vagina with wild-type virus, infection of the vaginal epithelium ranged from 1.0 to 2.5% of that measured in nonimmune mice, and at 72 h after vaginal challenge, no shed virus protein was detected in the vaginal lumen of immune mice whereas shed virus protein titers of 5,000 to 6,000 were present in nonimmune mice. No immune mice developed neurologic illness, whereas nearly all nonimmune mice died 8 to 14 days after challenge. The dose of challenge virus used in these studies was 1,000-fold higher than the minimum needed to cause lethal illness in nonimmune mice; thus, vigorous immunity was needed to suppress the challenge infections so effectively.

Antibody in vaginal secretions is an important component of immunity to vaginal HSV-2 infection. McDermott et al. (20) and Milligan and Bernstein (24) first demonstrated immunoglobulin G (IgG) antibodies specific for HSV-2 in vaginal secretions of young immune mice; antiviral IgA either was not detected or was detected at very low titers. We subsequently measured IgG viral antibody in vaginal secretions of adult immune mice at a mean enzyme-linked immunosorbent assay (ELISA) titer of 6,200, whereas the mean titer of viral secretory IgA (S-IgA) in the same secretions was 1.9 (30). The protective role of IgG and S-IgA in the vaginal secretions was investigated by neutralization and passive-transfer experiments (29). Affinity-purified IgG from vaginal secretions of adult immune mice, at its concentration in vivo in the vaginal mucus, effectively neutralized HSV-2, whereas S-IgA in the same secretions had little or no effect. Purified IgG from sera of immune mice provided significant protection against epithelial infection after passive transfer to nonimmune mice, even though the mean IgG anti-HSV-2 titers in sera and vaginal secretions of recipient mice at the time of challenge were only 29 and 7%, respectively, of the mean titers in standards prepared from actively immunized mice. The data indicated that IgG viral antibody in vaginal secretions of immune mice provided early protection against challenge infection by neutralizing virus in the vaginal lumen, whereas viral S-IgA contributed relatively little to protection.

A potential involvement of cell-mediated immunity in the mouse vaginal HSV-2 model was first indicated by the observation that adoptive transfer of lymphocytes from the iliac lymph nodes of immune mice protected naive mice against neurologic illness after vaginal challenge with wild-type virus (21). We have further investigated the role of T cells in vaginal immunity by in vivo depletion of these cells in immune mice 1 week before vaginal challenge (34). Depletion of T cells for this short period had no effect on antibody titers in vaginal secretions at the time of challenge. The results showed that immune mice depleted of CD4+ and CD8+ cells, Thy-1+ cells, or CD8+ cells alone had greater viral infection of the vaginal epithelium than did nondepleted immune mice. The T cells of...
immune mice thus inhibited infection of the vaginal epithelium within 24 h after inoculation of challenge virus.

The results summarized above indicate that vaginal immunization of mice with attenuated HSV-2 elicits a strong protective immune response in the vagina, consisting of T-cell immunity and viral IgG antibody in vaginal secretions. Parenteral immunization with viruses also typically stimulates both vigorous T-cell immunity and high titers of anti-viral IgG. It was thus of interest to ask whether parenteral immunization with attenuated HSV-2 would protect against vaginal challenge infection as effectively as vaginal immunization. Typically, levels of antiviral antibody and resistance to infection are greater at sites of antigenic stimulation than at distant sites; hence, immunity against virus infection is achieved most successfully by immunization at the sites that are directly involved in virus infection (25). However, the basis of enhanced immunity at sites of mucosal immunization is generally thought to be local production of specific S-IgA antibody, and vaginal immunization with HSV-2 induces mainly IgG viral antibody. Hence, it is unclear at present whether local vaginal immunization with HSV-2 would protect against reinfection any better than parenteral immunization. An answer to this question is critically important for the development of vaccines to protect the female genital tract against infections. The present studies were therefore designed to compare the immunity resulting from local immunization in the vagina to that resulting from immunization at three parenteral sites and in particular to determine whether vaginal immunization caused either local production of IgG viral antibody or selective homing of memory lymphocytes to the vagina.

MATERIALS AND METHODS

Animals and virus. Female BALB/c mice were purchased from Harlan/Sprague-Dawley, Indianapolis, Ind., and were 10 weeks old at the beginning of treatment. They were housed in compliance with all institutional and federal animal welfare requirements, and all experimental procedures were approved by the institutional Animal Care and Use Committee. Wild-type HSV-2 and attenuated HSV-2, a strain that contains a partial deletion of the thymidine kinase gene, as well as HSV-2-infected Vero cell lysates and uninfected Vero cell lysates, were generously provided by Mark McDermott, McMaster University, Hamilton, Canada (22).

Experimental design. One hundred seventy-five age-matched mice were allocated to seven groups of 25 mice each. Four groups were used to study immunity at 6 weeks after immunization in the vagina, peritoneal cavity, footpads, or pelvic lymph nodes. The fifth group served as a nonimmunized control for these cells. The sixth group was immunized in the vagina as described above, but its immunization was 6 weeks after immunization in the vagina, peritoneal cavity, footpads, or pelvic lymph nodes. The seventh group was immunized at three parenteral sites and in particular to determine whether vaginal immunization caused either local production of IgG viral antibody or selective homing of memory lymphocytes to the vagina.

Measurement of IgG concentrations by ELISA. Capture antibody (goat anti-mouse IgG1) (Sigma Chemical Co., St. Louis, Mo.) at 5 μg/ml was bound to Immunol 1 (Dynatech Laboratories, Alexandria, Va.) microtiter plate wells overnight in 0.1% pH 9.5 carbonate buffer at pH 9.5. After being washed in PBS, Tween 20, plate wells were blocked for 30 min with 2% normal goat serum in PBS–Tween 20. Serial twofold dilutions of samples in blocking medium were then placed in the wells and incubated overnight in a humid chamber. After being washed in PBS–Tween 20, the wells received horseradish peroxidase–goat anti-mouse IgG (Jackson Immunoresearch Laboratories) in PBS–Tween 20 for 2 h, followed by washing and addition of tetramethylbenzidine substrate. The sample antibody titer was defined as the reciprocal of the sample dilution at which the absorbance declined to 1.0, which was in the central, most linear part of the dilution curve. Control experiments demonstrated that background absorbance was 0.05 or less when immune and nonimmune samples were incubated on lysates of uninfected or infected Vero cells, respectively. Serum or vaginal secretion samples from the vaginal immunization group at 6 weeks were included each time samples from other groups were measured. Titers of other groups were thus always measured in direct comparison to vaginal group samples and are stated as a fraction of the geometric mean titer in the vaginal group. Vaginal secretion/serum titer ratios for each mouse were measured side by side on the same microtiter plate to minimize error in this measurement.

Tissues. Vaginas and uteri were fixed with 2% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4 (4°C, 2 h), and washed with PBS containing 10% sucrose and 2% DMSO (4°C, 2 h). Tissues were then immersed in cryoprotectant (0.5 M trehalose, 0.5 M sucrose, pH 7.4, 4°C, 2 h), and washed with PBS containing 1% DMSO and 10% sucrose (4°C, 2 h). Tissues were then placed in PBS containing 1% DMSO and stored at −70°C until needed. Cryostat sections (5 μm) were mounted on polylysine-coated slides, air dried, and stored with desiccant at −20°C until needed.

Quantitation of epithelial infection. Cryostat sections were fixed in methanol, blocked (30 min) in 2% normal goat serum, and labeled (60 min) with fluorescein isothiocyanate (FITC)–rabbit IgG anti-HSV-2 (Dako Corp., Carpinteria, Calif.). The specificity of labeling was confirmed by labeling negative and infected cell cultures (Ortho Diagnostic Systems, Inc., Raritan, N.J.), by labeling vaginal sections from infected and noninfected mice, and by using FITC-normal rabbit IgG. The percentage of vaginal epithelium infected by HSV-2 was determined with an image analysis system. A high-resolution RGB color camera with integration (AO-C-VI 470, Hyper HAD CCD; Optronix Engineering, Goleta, Calif.) was attached to the fluorescence microscope. Captured images were analyzed by using a MacIntosh computer (Quadra 840 AV) equipped with the LG-3 frame grabber (Scion Corp., Frederick, Md.) and with National Institutes of Health Image 1.55 (Wayne Rasband, National Institutes of Health). The lengths of HSV-2-labeled segments of vagina were measured in four histological sections, each derived from a different region of the vagina. The total length of vaginal epithelium was measured after staining with hematoxylin and eosin. The mean percentage of HSV-2-infected epithelium in each group was calculated, and the statistical significance of differences was evaluated by Student’s t-test.

Quantitation of plasma cells and lymphocytes. Cryostat sections were postfixed for 1 h in one of the following primary antibodies: rabbit anti-mouse IgA(α) or rabbit anti-mouse IgG(γ) (Jackson Immunoresearch Laboratories), rat anti-mouse CD4 or CD8 (Becton Dickinson, Mountain View, Calif.), or rat anti-mouse MHC class II (American Type Culture Collection). After blocking bovine serum antibody, antibody was FITC–goat anti-rabbit IgG (Jackson Immunoresearch Laboratories).
RESULTS

Antibody responses and protection. Immunization with attenuated HSV-2 at both vaginal and parenteral sites elicited IgG viral antibodies that were detected 6 weeks later in both sera and vaginal secretions (Table 1). Geometric mean IgG titters were 1.7- to 2.4-fold higher in sera and 4.7- to 18-fold higher in vaginal secretions of vaginally immunized mice than in the parenteral immunization groups. No infection of the vaginal epithelium was detected in any of the mice in the vaginal immunization group 24 h after vaginal challenge with wild-type virus (Table 1). In contrast, epithelial infection was found in all nonimmunized mice and in most parenterally immunized mice after challenge. The percentage of the vaginal epithelium that was infected was 12 ± 2% in the nonimmune group and ranged from 0.5 ± 0.1 to 1.9 ± 0.6% in the parenteral immunization groups. The highest level of epithelial infection in parenterally immunized mice was significantly lower than that in nonimmunized mice, indicating that parenteral immunizations induced immunity against vaginal challenge. The lowest level of epithelial infection in parenterally immunized mice was significantly higher than that in vaginally immunized mice, indicating that vaginal immunization provided the strongest protection against epithelial infection. All immunized mice, those immunized both vaginally and parenterally, were completely protected against the neurologic illness that developed in nonimmunized mice after vaginal challenge with the wild-type virus.

Local IgG production. Vaginal secretion and serum IgG anti-HSV-2 titters in each mouse were measured side by side on the same microtiter plate so that accurate vaginal secretion/serum titter ratios could be obtained. The mean vaginal secretion/serum titter ratio in the vaginal immunization group was 3.0- to 4.7-fold higher than that in the parenteral immunization groups (Table 2). The high titter ratio in vaginally immunized mice could have been due to increased transudation of serum IgG into the vaginal secretions. However, increased transudation would have increased the concentration of IgG in the vaginal secretions. The data in Table 2 indicate that the vaginal IgG concentration in vaginally immunized mice was higher than that in parenterally immunized mice but was not high enough to account for the high titter ratio. The high titter ratio might also be due to local production and secretion of virus-specific IgG in the vagina. In this case, the titer per unit of IgG concentration (specific antibody activity) in vaginal secretions would be higher than that in serum. The vaginal secretion/serum ratios of specific antibody activities were not significantly different from 1.0 in the parenteral immunization groups, indicating that IgG anti-HSV-2 titters per unit of IgG were the same in vaginal secretions and serum and that vaginal IgG was derived mainly from serum (Table 2). In contrast, the specific antibody activity ratio in the vaginal immunization group was 2.0 ± 0.2. This was significantly larger than 1.0 and indicated that specific viral IgG was produced in the vagina and released into vaginal secretions in amounts sufficient to double the virus-specific activity of the IgG in vaginal secretions in comparison to serum.

Plasma cells in the vagina. The number of IgG plasma cells in the vagina 6 weeks after vaginal immunization was 86-fold larger than that in the nonimmunized group (Fig. 1 and 2), while the numbers of IgG cells in the parenteral immunization groups were not significantly increased in comparison to those in the nonimmunized mice. Similarly, the number of IgA
plasma cells in the vagina was sevenfold larger in vaginally immunized mice than in nonimmunized mice, but there was no increase in that number in parenterally immunized mice. The numbers of both kinds of plasma cells in the vagina 24 h after challenge were also much larger in vaginally immunized mice than in any other groups (Fig. 1). To determine whether the increase in plasma cell numbers was restricted to the site of immunization, we counted such cells in uteri of all groups (Fig. 3). In contrast to the case for the vagina, most uterine plasma cells contained IgA. Vaginal immunization did not significantly increase the number of IgA plasma cells in the uterus, and all immunizations reduced the number of IgG plasma cells in the uterus.

**Lymphocytes in the vaginal mucosa.** The increased number of plasma cells in the vagina after vaginal immunization suggested that the numbers of other lymphoid cells might also be increased in the vagina by local immunization. Few lymphocytes were present in the vaginal mucosae of immunized or nonimmunized mice without vaginal challenge (Fig. 4). Lymphocyte numbers in the vaginal immunization group tended to be somewhat larger than those in the nonimmunized and parenterally immunized groups, but not all of the differences were statistically significant. After vaginal challenge, lymphocyte numbers in the immunized groups were 5- to 10-fold higher than those before challenge and also 5- to 10-fold higher than those in nonimmunized mice after challenge (Fig. 5). Vaginal challenge did not increase lymphocyte numbers in nonimmunized mice. The observations indicate that T- and B-lymphocyte numbers were rapidly increased in the vaginal mucosae of immunized mice after vaginal challenge, either by stimulation of resident memory lymphocytes or by recruitment of memory lymphocytes to the vagina from the blood. Among the four immunized groups after challenge, lymphocytes were marginally more numerous in vaginally immunized mice than in parenterally immunized mice.

**Lymphocytes in the vaginal epithelium.** Few CD8\(^+\) T cells were present in the vaginal epithelia of immunized or nonimmunized mice without vaginal challenge (Fig. 6). The number of these cells in vaginally immunized mice was modestly but significantly larger than those in the other groups. After vaginal challenge, the numbers of CD8\(^+\) cells in the immunized groups were 3- to 10-fold higher than those before challenge and 10- to 20-fold higher than those in the nonimmunized group after challenge. Vaginal challenge did not increase the number of CD8\(^+\) cells in the epithelia of the nonimmunized mice. More CD8\(^+\) cells were observed in the epithelia of vaginally immunized mice after challenge than in parenterally immunized mice, but the difference was not statistically significant. Collectively, the data indicate that the numbers of CD8\(^+\)
cells in the vaginal epithelium closely mirrored the numbers of CD4<sup>+</sup>, CD8<sup>+</sup>, and B220<sup>+</sup> cells in the vaginal mucosa.

Expression of MHC class II antigen in vaginal epithelium. Fluorescent staining of MHC class II antigens was bright on Langerhans cells within the vaginal epithelial layer of nonimmune mice 24 h after vaginal challenge, but the epithelial cells were unstained. In contrast, vaginally immunized mice exhibited maximal (3.0) staining of MHC class II antigens in vaginal epithelial cells 24 h after challenge, at which time the staining of Langerhans cells was entirely obscured by the epithelial staining. Staining of vaginal epithelial cells in parenterally immunized mice after vaginal challenge was intermediate: 1.2, 1.6, and 2.0 in the peritoneal, footpad, and pelvic groups, respectively. Upregulation of MHC class II antigens in the vaginal epithelium thus correlated with the increased numbers of T cells in the vaginae of immunized mice after vaginal challenge.

Duration of immunity. Immunization with live viruses typically stimulates long-lasting immunity. At 10 months after a single vaginal immunization with attenuated HSV-2, serum and vaginal secretion IgG anti-HSV-2 titers declined to about 20 to 30% of values measured at 6 weeks after immunization (Table 3). Similarly, the vaginal secretion/serum titer ratio, the titer ratio per unit of IgG concentration (micrograms per milliliter), and early protection against epithelial infection were each reduced in comparison to values measured at 6 weeks after immunization. However, the vaginal secretion/serum titer ratio in vaginally immunized mice at 10 months was still significantly higher than that in parenterally immunized mice at 6 weeks, and the vaginal/serum ratio of specific antibody activities was still significantly greater than 1.0, both observations indicating that local secretion of virus-specific IgG still occurred in the vagina 10 months after local immunization. The numbers of IgG and IgA plasma cells in the vagina remained elevated, especially after vaginal challenge (Fig. 7). Moreover, challenge virus increased the numbers of T and B lymphocytes in the vagina (Fig. 8) and upregulated expression of MHC class II antigens to a level of 1.2 in the epithelia of immunized mice but not in nonimmunized mice, indicating that substantial numbers of memory lymphocytes were still present. None of the immunized mice developed neurologic illness after challenge, whereas all nonimmunized mice died within 10 days.

**DISCUSSION**

Vaginal immunization of adult mice with attenuated HSV-2 has previously induced strong immunity against vaginal challenge infection with wild-type HSV-2 (32, 34). In the present study this immunization induced sterilizing immunity against a challenge inoculum that was 1,000-fold larger than the mini-
The number of CD8⁺ T cells in the vaginal epithelia of locally and parenterally immunized mice with and without challenge. The number of CD8⁺ T cells in the vaginal epithelia of vaginally immunized mice without challenge was significantly larger than those in the other groups (P = 0.013; five-group ANOVA). After challenge, the numbers of CD8⁺ T cells in the immunized groups were 3- to 10-fold larger than those before challenge (P < 0.0001 in all four tests; two-tailed t tests) and 10- to 20-fold larger than those in the nonimmunized group (P < 0.0001; five-group ANOVA). The numbers of CD8⁺ T cells in nonimmunized mice with and without vaginal challenge were not significantly different (P = 0.30; two-tailed t test). The number of CD8⁺ T cells after challenge was higher in vaginally immunized mice than in parenterally immunized mice, but the difference was not statistically significant (P = 0.074; four-group ANOVA).

The effectiveness of vaginal immunization with attenuated HSV-2 derives from a confluence of three key factors. First, highly immunogenic quantities of virus antigen are able to cross the epithelial barrier and reach lymphoid cells and lymphatic vessels in the vaginal stroma, because the virus penetrates the epithelium and replicates throughout the epithelial layer. Penetration of virus into the epithelial layer is facilitated by pretreatment of the mice with a progesterin, which thins and transforms the epithelium and increases its permeability to exogenous proteins (32). Similarly, we have found in preliminary studies that equivalent immunization as judged by viral antibody titers in serum can be achieved in estradiol-treated mice by vaginal inoculation of virus in conjunction with scarification of the vaginal epithelium. In contrast, nonreplicating and/or noninvasive antigens in the vagina produce only weak immune responses. This is evidenced by weak responses to nonreplicating protein antigens (12, 26, 27, 43) and weak responses to natural infections by replicating but noninvasive pathogens that colonize the superficial epithelial cells of the reproductive tract for weeks or months before elimination by an immune response (35). The latter organisms include Campylobacter fetus in cows (10); trichomonas species in cows (8, 9), mice (1), and humans (1); Candida albicans in rats and mice (7, 13); and papillomaviruses in animals and humans (6, 11). Chlamydial infection of the female genital tract in mice and guinea pigs also elicits only a modest convalescent immunity (39), which may be due in part to release of progeny organisms mainly into the genital tract lumen rather than the stroma.

Second, the effectiveness of vaginal immunization with attenuated HSV-2 is typical of the strong immunity that is induced by live-virus vaccination in general (2). Live viruses preserve conformation-dependent antigenic epitopes that are frequently the primary targets of neutralizing antibodies, and they selectively induce IgG antibodies of the IgG2a subclass in mice and of the IgG1 and IgG3 subclasses in humans (40). These complement-binding subclasses can be particularly effective in neutralization. For example, complement greatly increased neutralization of HSV-2 by virus-specific IgG2a monoclonal antibodies, and passive administration of IgG2a monoclonal antibodies to mice was much more protective against HSV-2 challenge than equal amounts of IgG1 monoclonal antibodies (15). The mouse IgG2a and human IgG1 and IgG3 subclasses also bind maximally to the high-affinity FcR type 1 on neutrophils and macrophages (40), making these subclasses the most effective opsonizing antibodies for phagocytosis. Live-virus antigens combine effectively with MHC molecules to elicit vigorous T-cell immunity, and they present sufficiently diverse B- and T-cell epitopes to overcome the genetic diversity of immune responses among individuals.

Third, the present study revealed that vaginal immunization with attenuated virus caused an 86-fold increase in the number of IgG plasma cells in the vaginal mucosa, correlated with a 3.0- to 4.5-fold elevation in the secretion/serum ratio of IgG anti-HSV-2 titers in comparison to that in parenterally immunized mice, whose vaginal plasma cell numbers were not increased. The main neutralizing antibody in the vaginal secretions of immune mice has previously been shown to be IgG (29). While most of the IgG plasma cells were localized in the stroma. In the periphery of the mucosa rather than near the epithelium, and while we do not have direct evidence of virus-specific cells among the plasma cells, it is likely that specific cells were present and that they account for the observed increase in specific viral antibody in the vaginal secretions. We assume

---

**TABLE 3. Immunity to vaginal challenge 10 months after vaginal immunization with attenuated HSV-2**

<table>
<thead>
<tr>
<th>Site of immunization</th>
<th>Conc of IgG (mean ± SEM):&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Geometric mean titer of IgG anti-HSV-2 (&lt;em&gt;n&lt;/em&gt;):&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Vaginal secretion/serum ratio&lt;sup&gt;b&lt;/sup&gt; (mean ± SEM)</th>
<th>Infection of vaginal epithelium No. of mice (%)&lt;sup&gt;b&lt;/sup&gt; (mean ± SEM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vagina</td>
<td>Serum (mg/ml): 1.8 ± 0.09, Vagina (μg/ml): 7.1 ± 0.81</td>
<td>Serum (10&lt;sup&gt;4&lt;/sup&gt;), Vagina (10&lt;sup&gt;2&lt;/sup&gt;) 6.2:3.2</td>
<td>Titer (10&lt;sup&gt;-3&lt;/sup&gt;) 6.8 ± 1.5, Sp act 1.3 ± 0.10</td>
<td>9/10:1.4 ± 0.7</td>
</tr>
<tr>
<td>None</td>
<td>Serum (mg/ml): 1.1 ± 0.10, Vagina (μg/ml): 2.6 ± 0.40</td>
<td>Serum (10&lt;sup&gt;4&lt;/sup&gt;), Vagina (10&lt;sup&gt;2&lt;/sup&gt;) 6.2:3.2</td>
<td>Titer (10&lt;sup&gt;-3&lt;/sup&gt;) 6.8 ± 1.5, Sp act 1.3 ± 0.10</td>
<td>10/10:6.4 ± 1.2</td>
</tr>
</tbody>
</table>

<sup>a</sup> The vaginal secretion/serum titer ratio was significantly larger than the titer ratios for the peritoneal, footpad, and pelvic groups at 6 weeks after immunization (P = 0.023; four-group ANOVA), and the vaginal secretion/serum ratio of specific antibody activities was significantly larger than 1.0 (P = 0.014; one-tailed t test).

<sup>b</sup> The percentage of vaginal epithelium that was infected in the vaginally immunized group was significantly lower than that in the nonimmunized control group (P = 0.0013; one-tailed t test).
that the IgG reached the vaginal lumen by transudation, which accounts for the presence of IgG in most mucosal secretions, although the cell biological details of this process have never been clarified (31). It is unlikely that the uterus was the source of increased specific IgG in the vagina, because vaginal immunization actually decreased the number of IgG plasma cells in the uterus.

As mentioned above, studies of the immune mechanisms that protect against vaginal HSV-2 infection in this mouse model have indicated that secretory immunity is mediated mainly by IgG antibody rather than IgA. The ELISA titer of IgG viral antibody in vaginal secretions of immune mice was much higher than that of IgA (30) and this IgG antibody neutralized HSV-2 far more effectively than the IgA (29). Vaginal immunization with nonreplicating protein antigens may also elicit mainly IgG rather than IgA antibodies in vaginal secretions (26, 43), as does vaginal infection with simian immunodeficiency virus in rhesus monkeys (23) and cervico-vaginal infection with HSV-2 in humans (4). The predominance of IgG antibodies in immune responses after vaginal immunization may be due to the fact that the cervix and vagina are relatively deficient in mucosal lymphoid nodules, where IgA responses are initiated (31). The available evidence also indicates that IgG antibodies in genital tract secretions are mainly responsible for immune protection against genital tract pathogens. In addition to HSV-2, this has been shown for chlamydiae in guinea pigs (38), C. fetus in cows (8, 9), and trichomonas species in cows (8, 9) and mice (1). The evidence of a primary role of secreted IgG antibodies in protection against genital tract infections in females is contrary to the widely accepted paradigm that IgA is the main protective antibody at mucosal surfaces, a discrepancy that has been noted previously by Patton and Rank (36). While the available evidence indicates that IgG is mainly responsible for secretory immunity in the female genital tract, this may result in part from the relative ease of inducing specific IgG in genital secretions, either by local or parenteral immunization. In contrast, a practical model should serve as a useful benchmark against which to compare other vaccine formulations and sites of immunization.

The increased numbers of plasma cells in the vagina after vaginal immunization could result from stimulation of resident precursor B cells, but this is unlikely because secondary lymphoid nodules, where B-cell stimulation and early differentiation normally occur, were not present in the vaginal mucosa either before or after immunization (32). Instead, secondary lymphoid follicles appeared in the iliac lymph nodes shortly after vaginal immunization with HSV-2 (30a), and this is the probable source of the B cells that later appeared as plasma cells in the uterus.

The main protective antibody in intestinal and upper respiratory tract secretions is IgA, and there is currently much interest in immunization at IgA-inductive sites such as the intestine, nasopharynx, and genital lymph nodes to protect the female genital tract against infections (33). These studies have shown that immunization at IgA-inductive sites can induce IgA responses in the female genital tract and can induce some degree of protection against genital tract infections, but at present there is no direct comparative evidence that such immunization is more protective than alternate routes of vaccination (35). Based on the results of the present study, it is unlikely that immunization at IgA-inductive sites would cause the development of IgG plasma cells in the genital tract or the local production of specific IgG antibody that we observed after vaginal immunization. Thus, while immunization at IgA-inductive sites may induce higher IgA titers in genital tract secretions than local immunization, it remains unclear which route of immunization would provide better protection against genital tract pathogens. This question can be answered only by assessments of protective immunity to each genital tract pathogen after local immunization in the genital tract in direct comparison to immunization at IgA-inductive sites. Such comparisons will often be complicated by differences in both the vaccines and the vaccination sites, since an effective vaccine formulation for one site will often not be effective at another site. In the case of HSV-2, the “gold standard” performance of vaginal immunization with attenuated virus in the mouse model should serve as a useful benchmark against which to compare other vaccine formulations and sites of immunization.

FIG. 7. Plasma cells in vaginae of immune and control mice 10 months after vaginal immunization. Vaginal IgG and IgA plasma cell numbers 10 months after vaginal immunization were significantly larger than those in nonimmunized control mice (P < 0.0001 in each test; two-tailed t tests). These numbers were further increased after vaginal challenge. Plasma cell counts were not done in control mice after challenge. m±sem, mean ± standard error of the mean.

FIG. 8. Lymphocytes in vaginae of immune and control mice 10 months after vaginal immunization. Vaginal lymphocyte numbers after vaginal challenge were 6- to 10-fold higher in mice that were immunized in the vagina 10 months previously than in nonimmune control mice (P < 0.0001 in all three tests; two-tailed t tests). m±sem, mean ± standard error of the mean.
cells in the vagina. The migration or homing of plasma cell precursors from the iliac nodes to the vagina was not an inherent property of iliac lymph node cells, since the pelvic immunization used in the present study targets the iliac lymph nodes (42) and induces secondary follicles in them (30a) but did not result in increased numbers of plasma cells in the vagina. Thus, while Lehner et al. (19) have suggested that T cells, B cells, and macrophages from the iliac lymph nodes of rhesus macaques preferentially home to the rectum and ascending colon, we conclude that there was no preferential homing of iliac lymph node plasmablasts to the mouse vagina. It thus appears that plasma cell precursors were recruited to the vagina from the blood by a factor(s) that was present in the vagina after vaginal immunization. The factor(s) might be antigen or a virus-induced chemokine, although no chemokine that attracts plasma cell precursors to tissues is currently recognized (5). If plasma cells are short-lived, the factor(s) must remain active in the vagina and continue recruiting plasmablasts for at least 10 months. Influenza virus infection increased the number of plasma cells in mouse lungs for at least 11 months (16), but plasma cell numbers were not increased in the vagina by vaginal infection with simian immunodeficiency virus (23). The latter observation has implications for vaccination to prevent heterosexual transmission of human immunodeficiency virus type 1 (HIV-1) in humans (35), since it suggests that vaginal immunization with attenuated HIV-1 would not cause local IgG production. Instead, vaginal immunization with a recombinant, epitheliotrophic virus such as HSV-2 expressing HIV-1 antigenic determinants might increase vaginal plasma cell numbers and elicit local production and secretion of neutralizing IgG antibody and thereby provide enhanced protection.

In view of the apparent recruitment of plasma cell precursors to the vagina by local immunization with HSV-2, it was important to investigate whether vaginal immunization also selectively increased the numbers of T and B lymphocytes in the vagina. Lymphocyte numbers in the vaginal mucosa were 1.2- to 3.0-fold larger in vaginally immunized mice than in nonimmunized and parenterally immunized mice. These results are consistent with data from a previous study utilizing vital dye tracing, in which the number of lymphocytes that migrated from the vaginal epithelium to the iliac lymph nodes was 3.5-fold higher in vaginally immunized mice than in nonimmunized mice (18). It is doubtful, however, that the larger number of vaginal lymphocytes in vaginally immunized mice was due to selective lymphocyte homing or stimulation of resident cells. Vaginal immunization induced 1.7- to 2.4-fold-higher viral antibody titers in serum than the three parenteral immunization groups (42) and induces secondary follicles in them (30a) but did not result in increased numbers of plasma cells in the vagina. Thus, vaginal immunization caused selective and long-lasting recruitment of lymphocytes to the vagina before antigen challenge, the effect was small and difficult to distinguish from effects on total lymphocyte numbers in the animal.

Vaginal inoculation of challenge virus causes a rapid accumulation of memory lymphocytes in the vaginal mucosa of immune mice. In the present study the numbers of CD4+, CD8+, and B220+ lymphocytes in the vagina increased 5- to 10-fold within 24 h after vaginally immunized mice were challenged. In the vaginal epithelia of these mice, the number of CD8+ cells per unit length increased 3.5-fold in vaginally immunized mice but did not increase in nonimmunized mice. Thus, vaginal inoculation of wild-type HSV-2 increased vaginal lymphocyte numbers within 24 h only when specific memory lymphocytes were present. Previously, we observed that MHC class II antigens in the vaginal epithelium were upregulated within 24 h after vaginally immunized mice were challenged in the vagina with HSV-2 but not when nonimmune mice were similarly challenged (32). This was presumably due to secretion of gamma interferon by memory T cells at the site of their reexposure to antigen in the vagina. Also, studies utilizing vital dye tracing revealed that the numbers of CD4+, CD8+, and B220+ lymphocytes migrating from the vaginal epithelium to the iliac lymph nodes increased 5- to 10-fold during the 24 h after inoculation of challenge virus into the vagina of vaginally immunized mice (18). Many, if not most, of the migrating T cells expressed the CD44 hi phenotype of mouse memory T cells. The 5- to 10-fold increase in the number of migrating cells observed by vital dye tracing corresponds well to the increased vaginal lymphocyte numbers observed in histological sections in the present study. Additionally, depletion of T cells from vaginally immunized mice in vivo by monoclonal antibodies 1 week before vaginal challenge significantly increased infection of the vaginal epithelium 24 h after challenge while having no effect on IgG viral antibody titers in vaginal secretions (34). This suggests that the memory T cells that accumulate in the vaginas of vaginally immunized mice during the 24 h after vaginal challenge are functionally important in immune protection of the epithelium.

The apparent recruitment of memory lymphocytes to the vagina by vaginal challenge in locally immunized mice raises the question whether such recruitment would occur after parenteral immunization. In the present study we found that vaginal lymphocyte numbers were markedly increased within 24 h after vaginal challenge in both vaginally and parenterally immunized mice but not in nonimmunized mice, indicating that memory lymphocytes were rapidly recruited to the vagina after challenge in immune mice irrespective of the site of immunization. Lymphocyte numbers were larger in the vaginally immunized mice but only by twofold or less. As in the case of immune mice without challenge, the larger numbers of vaginal lymphocytes in vaginally immunized mice may be due in part to larger total numbers of lymphocytes in the mice. Thus, vaginal immunization appeared to have little if any selective effect on lymphocyte homing to the vagina either before or after vaginal challenge. These results are in good agreement with recent studies reporting that mucosal immunization did not selectively increase the numbers of specific T cells in the lymph nodes draining mucosal tissues at 5 to 8 weeks after immunization in mice (14) and sheep (37). However, in contrast to the case for short times after immunization, Gallichan and Rosenthal (14) reported that memory T cells were selectively increased in lymph nodes draining mucosal sites at 5 to 19 months after mucosal immunization. This important observation suggests that local immunization at a mucosal site may elicit a more vigorous long-term cellular immunity against mucosal challenge than parenteral immunization.

ACKNOWLEDGMENTS

This work was supported by grant HD17337 from the National Institute of Child Health and Human Development.

We thank Sheila Scillufo, Li Ying, and Maureen Doran for excellent technical assistance.

REFERENCES


Immune and inflammatory responses to reproductive tract infection with *Trichomonas foetus* in immunized and control heifers. J. Parasitol. 82:594–600.


